MSB 2.51% 97.0¢ mesoblast limited

Ann: Mesoblast Update on COVID-19 ARDS Trial, page-356

  1. 102 Posts.
    lightbulb Created with Sketch. 7
    Just want to point out this covid trial hasn't been stopped for futility like has been said by a number of posters. They have been advised to continue to completion, so imo there must be some positive signs re secondary endpoints and maybe some mortality benefit (just not enough to pass primary endpoint)

    Hopefully enough positive data is gained to keep Novartis partnership.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.